Acumen Pharmaceuticals (NASDAQ: ABOS) holder to sell 8,143 shares

Rhea-AI Filing Summary

Acumen Pharmaceuticals, Inc. received a Form 144 notice for a planned sale of common stock. The filing covers 8,143 shares of common stock to be sold through Merrill Lynch on or about 01/08/2026 on the NASDAQ, with an aggregate market value of $14,815.32. The issuer reports 60,573,425 common shares outstanding.

The 8,143 shares were acquired on 01/07/2026 through the vesting of a restricted stock unit award granted under the company’s equity compensation plan. The seller, identified as Daniel OConnell, has also sold common stock in the past three months, including 4,649 shares on 01/05/2026, 5,102 shares on 01/06/2026, and 37,755 shares on 01/07/2026, with disclosed gross proceeds for each sale.

Insights

Equity compensation and insider-transactions analyst

Form 144 discloses an equity-award-related sale of 8,143 ABOS shares.

This Form 144 outlines a planned sale of 8,143 shares of Acumen Pharmaceuticals common stock on NASDAQ through Merrill Lynch, with an aggregate market value of $14,815.32. The shares were acquired one day earlier, on 01/07/2026, via vesting of a restricted stock unit award under the issuer’s equity compensation plan, indicating the transaction is directly tied to employee or executive equity compensation.

The seller, Daniel OConnell, has reported additional sales over the prior three days: 4,649, 5,102, and 37,755 shares of common stock, each with stated gross proceeds. These disclosures help clarify recent selling activity but do not, by themselves, describe the seller’s remaining holdings or overall exposure. The filing also includes the standard representation that the seller is not aware of undisclosed material adverse information regarding the issuer’s operations.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common stock	Merrill Lynch 225 Liberty St Floor 37 New York NY 10281	8143	14815.32	60573425	01/08/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common stock	01/07/2026	Vesting of restricted stock unit award	Acumen Pharmaceuticals, Inc.			8143	01/07/2026	Granted as part of issuer equity compensation plan

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Daniel OConnell 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/05/2026	4649	9163.33
Daniel OConnell 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/06/2026	5102	10031.44
Daniel OConnell 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/07/2026	37755	74980.95

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many Acumen Pharmaceuticals (ABOS) shares are covered by this Form 144?

The notice covers the planned sale of 8,143 shares of Acumen Pharmaceuticals, Inc. common stock, with an aggregate market value of $14,815.32.

How were the 8,143 Acumen Pharmaceuticals (ABOS) shares acquired?

The 8,143 common shares were acquired on 01/07/2026 through the vesting of a restricted stock unit award granted under Acumen Pharmaceuticals, Inc.’s equity compensation plan.

When and where are the ABOS shares in this Form 144 expected to be sold?

The filing lists an approximate sale date of 01/08/2026 for the 8,143 common shares, to be sold on the NASDAQ through Merrill Lynch.

Who is the selling security holder in this Acumen Pharmaceuticals (ABOS) Form 144?

The seller named in the Form 144 is Daniel OConnell, in whose account the Acumen Pharmaceuticals, Inc. common stock is to be sold.

What recent ABOS share sales by the same seller are disclosed?

The filing lists prior sales by Daniel OConnell in the last three months: 4,649 shares on 01/05/2026, 5,102 shares on 01/06/2026, and 37,755 shares on 01/07/2026, each with reported gross proceeds.

How many Acumen Pharmaceuticals (ABOS) shares are outstanding according to this notice?

The Form 144 states that 60,573,425 shares of Acumen Pharmaceuticals, Inc. common stock are outstanding.